pralsetinib RET-altered
Selected indexed studies
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. (Lancet Diabetes Endocrinol, 2021) [PMID:34118198]
- Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. (Thyroid, 2024) [PMID:38009200]
- Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports. (Oral Oncol, 2024) [PMID:39306936]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. (2021) pubmed
- RET kinase inhibitors for RET-altered thyroid cancers. (2022) pubmed
- [Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer]. (2021) pubmed
- Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. (2024) pubmed
- Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports. (2024) pubmed
- Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. (2022) pubmed
- Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer. (2024) pubmed
- Precision therapy for RET-altered cancers with RET inhibitors. (2021) pubmed
- RET-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity. (2023) pubmed
- RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions. (2024) pubmed